Drug Profile
Alteplase biosimilar - International Biotech Center Generium
Alternative Names: GNR-004; Revelise; Reveliza®Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator International Biotech Center Generium
- Developer International Biotechnology Center Generium
- Class Anti-ischaemics; Antihaemorrhagics; Antithrombotics; Cardiovascular therapies; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Fibrinolytic agents; Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction; Pulmonary embolism; Stroke
Most Recent Events
- 30 Aug 2018 Phase III development is ongoing for Myocardial infarction in Russia (International Biotech Center Generium Pipeline, August 2018)
- 26 Oct 2015 Phase-III clinical trials in Myocardial infarction in Russia (Parenteral) before October 2015